EW Stock Analysis: Edwards Lifesciences | NYSE
Medical Devices | NYSE, USA | Market Cap: 52.288m USD | 12M Return: 11% | US28176E1082 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 327M
EPS Trend: 68.6%
Qual. Beats: 2
Rev. Trend: 93.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Edwards Lifesciences Corporation is a global medical device company specializing in products and technologies for the treatment of advanced cardiovascular diseases, with operations in the United States, Europe, Japan, and other international markets. The companys portfolio centers on transcatheter heart valve therapies, including the Edwards SAPIEN family for aortic valve replacement and the PASCAL and EVOQUE systems for mitral and tricuspid valve repair and replacement. It also offers surgical structural heart solutions under brands such as INSPIRIS, KONECT RESILIA, and MITRIS RESILIA, distributing them through a direct sales force and independent distributors.
Founded in 1958 and headquartered in Irvine, California, the company operates in the Health Care Equipment sub-industry and is classified as a large-cap stock listed on the NYSE under the ticker EW. Its focus on transcatheter valve technologies positions it within a growing segment of the cardiovascular device market, driven by the shift from traditional open-heart surgery toward less invasive procedures that can reduce patient recovery times and surgical risk.
- TAVR revenue growth slows amid hospital staffing pressures
- Critical Care spin-off sharpens focus on heart valves
- PASCAL and EVOQUE drive mitral and tricuspid segment expansion
| Net Income: 1.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.85 > 1.0 |
| NWC/Revenue: 81.55% < 20% (prev 90.98%; Δ -9.43% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.72b > Net Income 1.00b |
| Net Debt (-3.44b) to EBITDA (2.00b): -1.73 < 3 |
| Current Ratio: 4.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (577.6m) vs 12m ago -1.75% < -2% |
| Gross Margin: 77.95% > 18% (prev 78.90%; Δ -0.95% > 0.5%) |
| Asset Turnover: 47.61% > 50% (prev 42.15%; Δ 5.46% > 0%) |
| Interest Coverage Ratio: 89.69 > 6 (EBIT TTM 1.83b / Interest Expense TTM 20.4m) |
| A: 0.38 (Total Current Assets 6.82b - Total Current Liabilities 1.51b) / Total Assets 13.9b |
| B: 1.07 (Retained Earnings 14.9b / Total Assets 13.9b) |
| C: 0.13 (EBIT TTM 1.83b / Avg Total Assets 13.7b) |
| D: 3.38 (Book Value of Equity 10.6b / Total Liabilities 3.14b) |
| Altman-Z'' = 10.45 = AAA |
| DSRI: 0.92 (Receivables 955.7m/902.6m, Revenue 6.51b/5.69b) |
| GMI: 1.01 (GM 78.90% / 77.95%) |
| AQI: 0.98 (AQ_t 0.37 / AQ_t-1 0.38) |
| SGI: 1.15 (Revenue 6.51b / 5.69b) |
| TATA: -0.05 (NI 1.00b - CFO 1.72b) / TA 13.9b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of August 24, 2026, the stock is trading at USD 89.79 with a total of 2,075,074 shares traded. Over the past week, the price has changed by -1.98%, over one month by +7.12%, over three months by +2.57% and over the past year by +11.04%.
Current recommended Stop Loss: 87.20 (which is 2.9% or 1.2 ATR below the current price).
Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold EW.
- StrongBuy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 101 | 12.4% |
P/E Trailing = 54.0536
P/E Forward = 30.4878
P/S = 8.0292
P/B = 4.9725
P/EG = 2.2046
Revenue TTM = 6.51b USD
EBIT TTM = 1.83b USD
EBITDA TTM = 2.00b USD
Long Term Debt = 598.7m USD (from longTermDebt, last quarter)
Short Term Debt = 24.1m USD (from shortTermDebt, last quarter)
Debt = 810.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 105.7m
Net Debt = -3.44b USD (calculated: Debt 810.1m - CCE 4.25b)
Enterprise Value = 48.8b USD (52.3b + Debt 810.1m - CCE 4.25b)
Interest Coverage Ratio = 89.69 (Ebit TTM 1.83b / Interest Expense TTM 20.4m)
EV/FCF = 34.07x (Enterprise Value 48.8b / FCF TTM 1.43b)
FCF Yield = 2.93% (FCF TTM 1.43b / Enterprise Value 48.8b)
FCF Margin = 22.01% (FCF TTM 1.43b / Revenue TTM 6.51b)
Net Margin = 15.43% (Net Income TTM 1.00b / Revenue TTM 6.51b)
Gross Margin = 77.95% ((Revenue TTM 6.51b - Cost of Revenue TTM 1.44b) / Revenue TTM)
Gross Margin QoQ = 77.56% (prev 78.21%)
Tobins Q-Ratio = 3.52 (Enterprise Value 48.8b / Total Assets 13.9b)
Interest Expense / Debt = 2.52% (Interest Expense 20.4m / Debt 810.1m)
Taxrate = 30.97% (439.0m / 1.42b)
NOPAT = 1.26b (EBIT 1.83b * (1 - 30.97%))
Current Ratio = 4.52 (Total Current Assets 6.82b / Total Current Liabilities 1.51b)
Debt / Equity = 0.08 (Debt 810.1m / totalStockholderEquity, last quarter 10.6b)
Debt / EBITDA = -1.73 (Net Debt -3.44b / EBITDA 2.00b)
Debt / FCF = -2.40 (Net Debt -3.44b / FCF TTM 1.43b)
Total Stockholder Equity = 10.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.35% (Net Income 1.00b / Total Assets 13.9b)
RoE = 9.69% (Net Income TTM 1.00b / Total Stockholder Equity 10.4b)
RoCE = 16.68% (EBIT 1.83b / Capital Employed (Equity 10.4b + L.T.Debt 598.7m))
RoIC = 10.47% (NOPAT 1.26b / Invested Capital 12.1b)
WACC = 7.16% (E(52.3b)/V(53.1b) * Re(7.24%) + D(810.1m)/V(53.1b) * Rd(2.52%) * (1-Tc(0.31)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.96 | Cagr: -1.97%
[DCF] Terminal Value 77.97% ; FCFF base≈1.26b ; Y1≈1.45b ; Y5≈2.13b
[DCF] Fair Price = 61.71 (EV 32.1b - Net Debt -3.44b = Equity 35.5b / Shares 575.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 68.58 | EPS CAGR: 2.50% | SUE: 1.28 | # QB: 2
Revenue Correlation: 93.04 | Revenue CAGR: 8.38% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.74 | Chg30d=-1.10% | Revisions=-65% | Analysts=23
EPS current Year (2026-12-31): EPS=3.00 | Chg30d=-0.30% | Revisions=-41% | GrowthEPS=+17.1% | GrowthRev=+11.4%
EPS next Year (2027-12-31): EPS=3.38 | Chg30d=+0.23% | Revisions=+40% | GrowthEPS=+12.6% | GrowthRev=+9.9%
[Analyst] Revisions Ratio: -20% (up=23, down=35)